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Abstract 
 
Carcinoembryonic antigen cell adhesion molecule-1 (CEACAM1) is a surface 
glycoprotein expressed on various blood cells, epithelial cells and vascular cells.  
CEACAM1 possesses adhesive and signaling properties mediated by its intrinsic 
immunoreceptor tyrosine-based inhibitory motifs that recruits SHP-1 protein-tyrosine 
phosphatase.  In this study, we demonstrate that CEACAM1 is expressed on the surface 
and in intracellular pools of platelets.  In addition, CEACAM1 serves to negatively 
regulate platelet collagen GPVI-FcR gamma chain signaling. Ceacam1
-/-
 platelets 
displayed enhanced Type I collagen and GPVI-selective ligand, collagen-related peptide, 
CRP-mediated platelet aggregation, enhanced platelet adhesion on Type I collagen and 
elevated CRP-mediated alpha and dense granule secretion.  Platelets derived from 
Ceacam1
-/-
 mice form larger thrombi when perfused over a collagen matrix under arterial 
flow compared to wild-type mice.  Furthermore, using intravital microscopy to ferric 
chloride-injured mesenteric arterioles, we show that thrombi formed in Ceacam1
-/-
 mice 
were larger and were more stable than wild-type mice in vivo.  GPVI depletion using 
monoclonal antibody JAQ1 treatment of Ceacam1
-/-
 mice showed a reversal in the more 
stable thrombus growth phenotype.  Ceacam1
-/-
 mice were more susceptible Type I 
collagen induced pulmonary thromboembolism than wild-type mice.  Thus, CEACAM1 
acts as a negative regulator of platelet-collagen interactions and thrombus growth 
involving collagen GPVI receptor in vitro and in vivo. 
 
 
 
 
 
 
 3 
Introduction 
 
In vivo, several negative regulatory mechanisms have been described that down modulate 
platelet-collagen interactions. These include prostacylin and nitric oxide released from 
endothelium and the immunoglobulin (Ig)-immunoreceptor tyrosine-based inhibitory 
motif (ITIM) superfamily member, PECAM-1 that serves an autoregulatory role when 
platelets come into contact with each other after exposure to collagen.
1-4 
 Given the 
importance of collagen in promoting platelet adhesion and thrombus formation 
particularly involving GPVI/FcR gamma chain signaling, it is essential that natural 
inhibitors that contribute to autoregulatory mechanisms that modulate collagen 
GPVI/FcR gamma chain-mediated signaling are characterized in platelets.   
 
While the ITIM -bearing receptor regulation of ITAM-associated pathways has been well 
described in the leukocyte world, they are poorly defined in platelets.  This concept is 
further complicated by the observation that Ig-ITIM-bearing receptors have the capacity 
to bind multiple phosphatases including SHP-1, SHP-2 and SHIP to initiate signaling 
attenuation.
5 
 However, there is also evidence that Ig-ITIM bearing receptors may 
differentially associate with distinct phosphatases depending upon the cellular context 
and activational status of cells.
6,7   
 
These inhibitory mechanisms are further complicated by the fact that ITAM-bearing 
receptors can mediate inhibitory ITAM signaling under defined conditions using either 
DAP12 adaptor or FcR gamma chain.
8,9 
 This switch between activating and inhibitory 
ITAM signaling is controlled by the avidity of the ligand cross-linking the receptor.  It 
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appears that low-avidity ligand interactions result in inhibitory signaling possibly 
involving a phosphatase and high-avidity ligand interactions produce activating ITAM-
mediated signaling.
8,9 
 Therefore, it is important to dissect out the respective mechanisms 
of activation and inhibitory mechanisms in platelets. 
 
As platelets lack the prototypic inhibitory Ig-ITIM superfamily member, FcgammaRIIb, 
there has been a prevailing view that PECAM-1 represents the sole surrogate Ig-ITIM 
superfamily member that serves a negative regulatory role.
1,2
  However, based upon 
several studies it would appear that platelets contain multiple Ig-ITIM superfamily 
members that are likely to have a modulatory role in regulating platelet-collagen 
interactions.  Several reports suggest that platelets contain other Ig-ITIM superfamily 
members including G6B and TREM (TLT-1) that may attenuate platelet function.
10,11 
 In 
immunological systems, SHP-1 protein-tyrosine phosphatase is classified as a negative 
regulator, while in collagen GPVI platelet responses, it has been proposed to act as a 
positive regulator.
12
  Given this controversy, it is important that we study respective Ig-
ITIM superfamily members that are linked to distinct protein-tyrosine phosphatases such 
as SHP-1 in platelets to determine their relative importance in regulating platelet 
thrombus formation. 
 
Carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1/CD66a/Bgp) is 
a member of the CEACAM family of genes that is a type I-transmembrane receptor that 
is broadly expressed on a wide range of cells including immune, haematological, 
epithelial and endothelial cells.
13
  CEACAM1 is the only CEACAM superfamily member 
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expressed in rodents and humans.  It shares some similarities to PECAM-1 in its capacity 
to mediate homophilic and heterophilic ligands (CEA and CEACAM6) but generally has 
a preference towards homophilic CEACAM1 interactions.
13
  CEACAM1 is composed of 
an N-terminal IgV-like domain that is responsible for homophilic adhesion, followed by 
one to three IgC-like domains in its extracellular structure.  In addition, alternative 
mRNA splicing gives rise to different isoforms that differ in length of their cytoplasmic 
domain including the long ITIM-containing isoform (CEACAM1-L)(70-73 amino acids) 
or a short ITIM-less isoform (CEACAM1-S) (10-12 amino acids).
13
  The long form of 
CEACAM1 protein has two ITIMs that preferentially recruit SHP-1 protein-tyrosine 
phosphatase and to a lesser extent SHP-2 protein-tyrosine phosphatase.
14,15 
 Based upon 
recent studies in T-cells, CEACAM1 functions as a negative regulator via its recruitment 
and activation of SHP-1 protein-tyrosine phosphatase.
16  
However, there is little known 
about the presence and functional role of CEACAM1 in regulating platelet-collagen 
interactions and thrombus formation in vitro and in vivo. The only exception was a report 
by Hansson et al., 1990 which suggested that C-CAM (old terminology) was present in 
the intracellular compartment of rat platelets.
17
     
 
In this current study, we provide the first report that CEACAM1 serves as a negative 
regulator of platelet-collagen interactions, thrombus growth in vitro and in vivo and 
susceptibility to Type I collagen-induced pulmonary thromboembolism.  Based upon 
these studies, we propose CEACAM1 as a new negative regulator in platelets that serves 
an autoregulatory role when platelets come into contact with each other after exposure to 
collagen. 
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Materials and Methods 
 
Materials 
Antibodies 
Rabbit anti-mouse CEACAM1 has been previously described.
18 
 Anti-rabbit FITC was 
purchased from Dako Australia (Glostrup, Denmark).  Anti-mouse GPVI
19
, anti-mouse 
GPIbα/IX/V complex20, anti-mouse integrin α2121, anti-mouse CD922 anti-mouse GPVI 
(JAQ1)
23
 were purchased or obtained from Emfret analytics (Wurzburg, Germany).  
Anti-mouse integrin αIIb324, anti-mouse CD4425 and HRP-conjugated anti-
phosphotyrosine RC20 antibody were obtained from BD Biosciences Pharmingen 
(Franklin Lakes, NJ).  Anti-mouse ‘390’ PECAM-1 antibody was provided by Dr. Steve 
Albelda (Philadelphia, PA).
26 
PLC2 and ERK-2 antibodies were purchased from Santa 
Cruz (Santa Cruz, CA). 
 
Mice 
The generation of Ceacam1
-/-
 mice and breeding on C57BL/6 background has been 
described.
18 
 Wild-type and Ceacam1
+/-
 mice were age- and sex-matched C57BL/6.  
These mice were housed in the Burnet Institute at Austin Animal House and the St. 
Michael’s Hospital Research Vivarium.  All procedures were approved by the Austin 
Health Animal Ethics committee #2005:2098 and #2005:02354, and Animal Care 
Committee of St. Michael’s Hospital. 
 
Preparation of mouse platelets 
 7 
Platelet-rich plasma (PRP) or washed mouse platelets were prepared as previously 
described.
26 
  
 
Static platelet adhesion assays 
Static platelet adhesion assays were performed according to Yuan et al., 1999.
27
  Washed 
platelets derived from wild-type, Ceacam1
+/-
 and Ceacam1
-/-
 mice were examined for 
binding to immobilised Type I fibrillar collagen and fibrinogen in the absence of Mg
2+ 
over time, fixed and quantitated by differential interference contrast (DIC) microscopy 
(x63 oil objective). 
 
Platelet adhesion and thrombus formation under flow 
Platelet adhesion and thrombus formation under flow was performed as previously 
described.
1
    
 
Platelet aggregation assays 
Platelet aggregation assays were monitored by measuring light transmission using a 4-
channel platelet aggregometer (Chronolog, Havertown, PA).
27,29  
Platelet rich plasma 
(PRP) was diluted in RCD buffer,
 
pH 7.4, (108 mM NaCl, 38 mM KCl, 1.7 mM 
NaHCO3, 21.2 mM sodium citrate, 27.8 mM glucose and 1.1 mM MgCl2.6H2O) to 
generate a platelet count of 100x10
9
/L.  Reactions were performed in glass cuvettes in a 
250 μL volume in the presence of 100 μg/ml fibrinogen and 1 mM CaCl2 at 37
o
C with 
constant stirring (1000 rpm).   
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Flow cytometry 
The surface and intracellular expression of CEACAM1 was performed essentially as 
previously described.
30
 The only exception was that platelets were labelled with either 
preimmune rabbit serum (1:500), rabbit anti-mouse CEACAM1 2457 serum (1:500) or 
FITC-conjugated antibody to P-selectin (10 μg/mL) and where appropriate then labelled 
with swine anti-rabbit F(ab’)2 FITC-conjugated antibody (1:200)(Dako Australia, 
Glostrup, Denmark). 
   
5-Hydroxytryptamine dense granule secretion 
Dense granule secretion was performed essentially as described with the inclusion of 2 
mM Imipramine hydrochloride (Sigma Chemical Co., St. Louis, MO).
1 
 
Ferric chloride-induced model of thrombosis and intravital microscopy 
Wild-type, Ceacam1
+/-
 or Ceacam1
-/-
 C57BL/6 mice (4-5 weeks old) were anaesthetized 
with a ketamine/xylazine (200:10 mg/kg) mixture and the mesentery was exteriorized 
through a midline abdominal incision. A catheter was inserted into the jugular vein to 
deliver rhodamine dye and anaesthetic as required. Mesenteric arterioles (60-100 µm in 
diameter) were visualized with a Zeiss Axiovert 135 M1 microscope (Carl Zeiss, 
Gottingen, Germany), and z-stack slices of the vessel captured with a AxioCam MRm 
camera. A strip of filter paper (1 x 4 mm) was dipped in a 462 mM (7.5% w/v) FeCl3 
solution for 3 seconds, applied to a 2 – 5 mm length of arteriole for 4 minutes and then 
removed.
30,31
 Z-stack images of the vessel were taken over five 2 minute cycles 
(determined as the time the vessel begins to occlude). The rendered z-stack images were 
deconvolved with AxioVision Rel 4.6 software, to produce a three-dimensional image, 
and the volume of the thrombi were determined from the area and height of the clot.  
Assessment of platelet thrombi was blinded to detect quantitative differences between 
wild-type, Ceacam1
+/-
 and Ceacam1
-/-
 mice.   Stability was determined by calculating the 
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percentage of the vessel that is occupied by the thrombus over a period of 2 minutes, and 
scored from 1 – 10, with 1 being 0 – 10% occupancy and 10 being 91 – 100% occupancy 
(i.e. complete vessel occlusion). 
 
Pulmonary Thromboembolism mouse model 
Mouse models of pulmonary thromboembolism were essentially performed as previously 
described.
32 
 The only exceptions include that 350 μg/kg of type I fibrillar collagen and 
0.200 μl/g tissue thromboplastin (Thromborel S) were used in respective models.  The 
endpoint of the pulmonary thromboembolism was defined as the time to restrained 
breathing within 10 second intervals.        
 
Statistical analysis 
 
Data was checked for normal distribution using the Shapiro-Wilk normality test and 
statistical significance was determined using unpaired Student’s t test.  P values of 0.05 
or less were taken to indicate significant differences. 
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Results 
CEACAM1-deficient mice have normal haematopoiesis 
Unlike other CEACAM1 family members, CEACAM1 is broadly expressed on a wide 
range of cells including immune, epithelial cells, endothelial cells and platelets.
13
 In order 
to test if deletion of CEACAM1 influenced haematopoiesis and particularly platelet 
production, we determined peripheral blood haematological parameters on age- and sex 
matched wild-type versus CEACAM1-deficient mice.  As shown in Table 1, Ceacam1
-/-
 
mice displayed normal white blood cell (WBC) count, red blood cell (RBC) count and 
parameters including haemoglobin and platelet count compared to wild-type C57BL/6 
mice (P>0.05, n=18).  Differential counting of white blood cells revealed that Ceacam1
-/-
 
mice had an increased percentage of neutrophils compared to wild-type mice (*P<0.05, 
n=18). 
 
CEACAM1 is expressed on the surface and in intracellular pools in murine and 
human platelets 
 
The only evidence in the literature in relation to CEACAM1 in platelets was the 
demonstration that C-CAM (old terminology) was present in the intracellular 
compartment of rat platelets.
17  
In order to determine the presence of CEACAM1 protein 
expressed on the surface and intracellular pools of resting murine and human platelets, 
and if this expression is upregulated by intracellular granule release, we examined the 
binding of specific polyclonal anti-murine CEACAM1 antibody to either resting and 
thrombin-stimulated wild-type murine and human platelets, monitored by flow 
cytometry.  In order to characterize the surface expression of CEACAM1 in murine 
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platelets, washed platelets were incubated with either normal rabbit pre-immune serum 
(1/500 dilution) or polyclonal anti-mouse CEACAM1 antibody (1/500 dilution) followed 
by FITC-labelled anti-rabbit conjugate (1/200 dilution) and then analyzed by flow 
cytometry.  In addition, characterization of the total distribution of CEACAM1 in murine 
platelets was determined by permeabilization of the platelet membrane with 0.1% (w/v) 
saponin treatment.  As shown in Figure 1A and C, a two-fold increase in the mean 
fluorescence intensity was observed in resting murine platelets using a specific 
polyclonal anti-CEACAM1 antibody compared to normal rabbit pre-immune serum 
(1/500 dilution) (15.24±1.61 □; vs 7.74±1.71; ■; n=3, **P<0.005), indicating the 
presence of CEACAM1 on the surface of murine platelets.  In addition, a four-fold 
increase in the mean fluorescence intensity (MFI) was observed in saponin-treated 
murine platelets using a specific polyclonal anti-CEACAM1 antibody compared to 
normal rabbit pre-immune serum (1/500 dilution) (43.64±8.84 □; vs 11.99±2.75, ■, n=3, 
*P<0.05), indicating the presence of CEACAM1 in an intracellular distribution in murine 
platelets.  As shown in Figure 1B and D, a seven-fold increase in the MFI was observed 
in resting human platelets using a specific monoclonal anti-CEACAM1 antibody 
compared to an isotype control antibody (35.3±1.3 □, vs 4.0±1.2; ■, **P<0.005, n=3).  In 
addition, a four-fold increase in the MFI was observed in saponin-treated human platelets 
using a specific monoclonal anti-CEACAM1 antibody compared to an isotype control 
antibody (50.25±17.4 □, vs 12.05±0.35 ■, *P<0.05, n=3).  Cell surface expression of 
CEACAM1 was increased upon agonist stimulation with different doses of thrombin 
compared to resting murine platelets and normal pre-immune rabbit serum (24.08±2.3 □, 
vs 15.25±0.93 □, *P<0.05, n=3; 8.41±0.37 ■)(Figure 1E).  A similar trend was observed 
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with cell surface expression of CEACAM1 following agonist stimulation with different 
doses of thrombin compared to resting human platelets and negative isotype antibody 
(58.93±7.11 □, vs 31.63±2.59 □, *P<0.05, n=3; 10.23±1.15 ■)(Figure 1F).  At higher 
concentrations of thrombin, a modest reduction in CEACAM1 surface expression is 
observed.  Ceacam1
+/-
 platelets had 60% ceacam1 expression compared to wild-type 
murine platelets (Figure 1G-H).  These results indicate that CEACAM1 is expressed on 
the surface and in intracellular pools of resting murine and human platelets.    
 
CEACAM1 serves as a negative regulator of collagen GPVI-mediated platelet 
responses 
Recent studies in T-cells have demonstrated that CEACAM1 acts as an inhibitory co-
receptor via the interface of its intrinsic ITIMs with recruitment and activation of SHP-1 
protein-tyrosine phosphatase.
16  
This finding supports the concept in immunological 
systems that SHP-1 protein-tyrosine phosphatase acts as a negative regulator.
33  
However, 
in collagen GPVI-mediated platelet responses, SHP-1 has been proposed to act as a 
positive regulator.
34 
 Given this controversy, it is important to define the functional role 
of CEACAM1 negative regulatory signaling in platelets.  In order to test the hypothesis 
that CEACAM1, like PECAM-1, normally functions to modulate collagen GPVI-
mediated platelet responses, we first examined the ability of platelets derived from wild-
type versus CEACAM1-deficient mice to bind to immobilised Type I fibrillar collagen 
and fibrinogen in the absence of Mg
2+ 
over time.  As shown in Figure 2A,  Ceacam1
-/-
 
platelets bound significantly better at all time points on Type I fibrillar collagen 
compared to wild-type and Ceacam1
+/- 
platelets (***P<0.005, n=3).  This effect was 
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specific as adhesion of bovine serum albumin over the same time points was insignificant 
for both wild-type, Ceacam1
+/-
 and Ceacam1
-/-
 platelets.  This hyper-responsive platelet 
adhesion observed with Ceacam1
-/-
 platelets was selective for Type I fibrillar collagen as 
platelet adhesion on fibrinogen did not show increased adhesion (Fig. 2B).  In fact, a mild 
reduction in platelet adhesion on fibrinogen is observed in Ceacam1
-/-
 platelets but not 
wild-type or Ceacam1
+/-
 platelets (*P<0.05, n=3). 
 
In order to examine the functional role of CEACAM1 negative regulatory signaling in 
platelets, we performed a time course (0-3 min) of CRP stimulation of wild-type and 
Ceacam1
-/-
 platelets and determined global tyrosine phosphorylation profiles of 30 μg of 
platelet lysates.  As shown in Figure 3A, CRP stimulation of Ceacam1
-/-
 platelets showed 
an increased level of tyrosine phosphorylation of a number of proteins including Syk over 
time with both quantitative and kinetic differences than wild-type platelets.  In addition, 
Erk-2 blot was included as a loading control (lower panel).  Measurement of tyrosine 
phosphorylation of PLC2 was performed by immunoprecipitation of resting versus CRP 
stimulated wild-type and Ceacam1
-/- 
platelets (T=90 secs) followed by immunoblotting 
with an anti-phosphotyrosine antibody (Fig. 3B).  PLC2 antigen loading was confirmed 
by reprobing with a polyclonal anti-PLC2 antibody.  As shown in Fig. 3B, resting and 
CRP stimulated Ceacam1
-/-
 platelets showed increased tyrosine phosphorylation of 
PLC2 compared to wild-type platelets.  These results support the concept that 
CEACAM1 acts as a negative regulator to modulate ITAM-coupled signaling pathways. 
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As CEACAM1 has been demonstrated to function as an regulator in T cells upon TCR 
ligation, we wanted to test the hypothesis that CEACAM1 serves to negatively regulate 
ITAM-bearing collagen GPVI-mediated platelet responses.  In order to test the possibility 
in platelets, a comparison of the ability of platelets derived from wild-type and 
CEACAM1-deficient mice in platelet aggregation responses over a dose-dependent range 
of GPVI selective agonist, CRP (0.62-2.5 μg/mL)(j-l) and acid soluble Type I collagen 
(1.5-4 μg/mL)(m-o) with G-protein coupled agonists, PAR-4 (100-250 μM)(a-c), ADP 
(5-20 μM)(d-f) and calcium ionophore (CI)(0.3-2.5 μg/mL)(g-i).  As shown in Figure 4, 
wild-type and Ceacam1
-/- 
platelets display equivalent platelet aggregation profiles over a 
dose-dependent range of PAR-4, ADP and calcium ionophore.  In contrast, Ceacam1
-/-
 
platelets show enhanced amplitude and slope of platelet aggregation responses to CRP 
and collagen particularly at subthreshold doses.  This hyper-responsive effect is 
independent of GPVI expression and other platelet glycoprotein expression (integrin 
α21, GPIb-IX-V complex, integrin αIIb3, CD9, CD44, PECAM-1) as Ceacam1-/- 
platelets are comparable to wild-type platelets (Table 2).  These results indicate that the 
absence of the Ig-ITIM superfamily member, CEACAM1 leads to hyper-responsive 
GPVI-mediated platelet responses to collagen and CRP. 
 
 As Ceacam1
-/-
 platelets displayed enhanced adhesion of Type I fibrillar collagen and 
hyper-responsive GPVI-mediated platelet aggregation responses, we wanted to determine 
if the absence of CEACAM1 influenced the platelet release reaction stimulated with 
GPVI-specific agonists is restricted to GPVI.  In order to test this possibility, we 
compared the ability of wild-type, Ceacam1
+/-
 and Ceacam1
-/-
 platelets to secrete alpha 
 15 
(P-selectin) and dense granule serotonin upon stimulation of GPVI.  As shown in Figure 
5A-B, Ceacam1
-/-
 platelets displayed increased release of their alpha and dense granules 
at subthreshold doses of fibrillar collagen and CRP compared to low or high doses of 
thrombin treated wild-type and Ceacam1
+/- 
platelets (*P<0.05, ***P<0.001, n=3).  These 
data are consistent with the concept that CEACAM1 normally acts as a negative regulator 
of platelet GPVI-mediated alpha and dense granule release. 
 
CEACAM1-deficient mice display increased thrombus growth in vitro, in vivo and 
enhanced susceptibility to Type I collagen induced pulmonary thromboembolism 
While platelets lack the prototypic Ig-ITIM superfamily member, FcRIIb, other 
surrogate Ig-ITIM superfamily members, like PECAM-1, serve as potent negative 
regulators of platelet thrombus formation.  It is however, not clearly defined which Ig-
ITIM superfamily members are functionally important in regulating in vivo platelet 
thrombus formation and this issue warrants investigation.  In order to explore the 
possibility that CEACAM1 is important in modulation of platelet thrombus formation in 
vivo, we compared age- and sex-matched wild-type versus Ceacam1
-/- 
mice in platelet 
adhesion and thrombus growth on exposed extracellular matrix of the injured mesenteric 
arterioles (60-100 μm sized vessels) as a vascular injury model by ferric chloride-
mediated denuding of endothelium monitored by fluorescence intravital microscopy.  The 
ferric chloride (FeCl3) oxidative injury model was used to induce formation of free 
radicals to disrupt the vascular endothelium in mesenteric arterioles.
30 
 Platelet thrombus 
formation is monitored in real time by assessing the accumulation of fluorescently 
labelled platelets.  Following application of FeCl3 to the mesentery, platelets in both 
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wild-type and Ceacam1
-/-
 mice rapidly commenced interacting with the injured vessel 
wall and within 10-15 mins after the injury, vessel occlusion occurred.  Thrombus 
characteristics were assessed in real time measuring the area (μm2), height (μm) and 
volume (μm3) occupied by the thrombus together with a stability score for each thrombus 
over a 2 min time frame.  Typically, Ceacam1 -
-- /// --- mice showed increased thrombus growth 
and more stable thrombi over time compared to wild-type control mice (Fig. 6A). 
Typically, Ceacam1
-/-
 arterioles showed an increase in thrombus area (reflecting surface 
coverage of platelets) over a 2 minute time interval compared to wild-type and 
Ceacam1
+/-
 arterioles (6212±268.7 vs 3294±223.4 and 2859±293.9µm
2
; ***P<0.0001, 
n=15)(Fig. 6B). In addition, Ceacam1
-/-
 mice developed thrombi that were significantly 
larger in volume compared to wild-type and Ceacam1
+/- 
mice (122400±6794 vs 
49430±4602 and 63680±5478µm
3
; ***P<0.0001, n=15) (Fig. 6C).  Moreover, the 
thrombi formed in Ceacam1
-/-
 arterioles were typically more stable than those in wild-
type and Ceacam1
+/- 
arterioles (4.067±0.3712 vs 2.400±0.2138 and 1.05±0.12; 
***P<0.001, n=15)(Fig. 6D).  In contrast, Ceacam1
-/-
 mice showed no abnormality in 
time to first thrombi > 20 µm
2
, number of thrombi > 20 µm
2
, the increase in thrombus 
diameter over 1 min, thrombus height and time to vessel occlusion (P>0.05, n=15) (data 
not shown).  In order to directly test the contribution of collagen GPVI receptor in this 
thrombus growth phenotype in ceacam1
-/-
 arterioles, we deleted GPVI in vivo using JAQ1 
treatment (100 μg/mouse) and left for 5 days before ferric chloride injury and intravital 
studies
23
.  A different cohort of ceacam1
-/-
 were similarly treated with control IgG (100 
μg/mouse).  As shown in Figure 6E-F,  JAQ1 treated Ceacam1-/- mice showed a 3-fold 
reduction in thrombus volume and 2-fold reduction in stability score compared to control 
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IgG treated and untreated Ceacam1
+/+
 and Ceacam1
-/-
 arterioles (n=10 arterioles from 3 
mice/group; ***P<0.001).  Importantly, Ceacam1
-/-
 arterioles showed reversal of the 
more stable thrombus phenotype upon JAQ1 treatment and in thrombus growth 
phenotype compared to Ceacam1
+/+
 arterioles. We confirmed successful clearance of 
GPVI after JAQ1 treatment by western blotting of platelet lysates from Ceacam1
-/-
 
platelets (not shown).  This data supports the concept that the in vivo thrombus growth 
phenotype in ceacam1
-/- 
arterioles is dependent on presence of collagen GPVI receptor. 
 
To further investigate the role of CEACAM1 in modulating platelet thrombus formation 
on immobilized collagen, in vitro flow studies were performed with blood obtained from 
wild-type, Ceacam1
+/-
 and Ceacam1
-/-
 mice.  DiOC6-labelled whole blood was perfused 
through Type I collagen-coated microcapillary tubes at a wall shear rate of 1800 seconds
-
1
, and thrombi were imaged at 4 minutes of blood perfusion by confocal microscopy.  
Ceacam1
-/-
 platelets (136200±18640 μm3) displayed increased thrombus volume than 
wild-type (83870±8065 μm3) or Ceacam1+/- platelets (86640±15330 μm3) (P<0.05, 
n=9)(Fig. 6F).  Collectively, these data demonstrate that CEACAM1 is required for 
modulation of platelet-collagen interactions in platelet thrombus growth in vitro and in 
vivo. 
 
To further determine the consequences of CEACAM1 deficiency in vivo, we tested wild-
type, Ceacam1
+/-
 and Ceacam1
-/- 
mice in a model of pulmonary thromboembolism 
induced by infusion of type I fibrillar collagen or tissue thromboplastin.  Typically, 
Ceacam1
-/-
 mice displayed enhanced susceptibility to Type I collagen induced pulmonary 
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thromboembolism than wild-type and Ceacam1
+/-
 mice with >70% reduction in 
circulating platelet counts within 3 minutes of challenge (Figure 7A-B).  Following 
challenge with Type I fibrillar collagen, Ceacam1
-/- 
mice reached maximal clinical 
scoring of restrained breathing earlier than wild-type and Ceacam1
+/-
 mice (252.1±15.39 
versus 343.5±23.73 and 327.0±28.29 secs; **P<0.005; n=20).  In this system, both wild-
type, Ceacam1
+/-
 and Ceacam1
-/-
 mice had comparable reductions in circulating platelet 
numbers over a three minute time frame tested following challenge with type I fibrillar 
collagen (73.49±3.15 versus 77.24±2.25 and 74.21±3.50%; P>0.05, n=20).  It should be 
noted that early time points could not be tested for detection of kinetic differences in 
platelet consumption due to animal welfare considerations.  Consistent with these 
observations, histologic sections of lung tissue and analysis of occlusive thrombi in the 
lungs at the end of the experiment revealed similar numbers of occluded vessels between 
wild-type, Ceacam1
+/-
 and Ceacam1
-/- 
mice (data not shown).  In contrast, wild-type and 
Ceacam1
-/-
 mice were equally susceptible and had comparable reductions in circulating 
platelets over time following tissue thromboplastin-induced pulmonary 
thromboembolism (Figure 7C-D)(P>0.05, n=10).  Collectively, these data highlight that 
CEACAM1 regulates platelet-collagen interactions in controlling susceptibility to Type I 
collagen-induced pulmonary thromboembolism in vivo.      
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Discussion 
Using several approaches, we have defined a novel role of CEACAM1 as a new 
inhibitory co-receptor in murine platelets that serves to negatively modulate platelet-
collagen interactions and regulate platelet thrombus formation in vitro and in vivo.  This 
study suggests that CEACAM1 serves an autoregulatory role when platelets come into 
contact with each other when exposed to Type I collagen.  Firstly, CEACAM1 is 
expressed on the surface and in intracellular pools of murine and human platelets.  
Secondly, CEACAM1 serves as a negative regulator of collagen GPVI-mediated platelet 
responses in vitro.  Thirdly, CEACAM1 serves to negatively regulate platelet thrombus 
formation in vitro and in vivo under conditions where Type I collagen is exposed in the 
injured arteriole and in the presence of collagen GPVI receptor on platelets.  Finally, 
CEACAM1 serves as a negative regulator of thrombosis following Type I collagen-
induced pulmonary thromboembolism in vivo.     
  
There is little evidence in the literature in relation to the presence and functional role of 
CEACAM1 in platelets.  The only exception is a report by Hansson et al., 1990 which 
suggested that C-CAM (old terminology) was present in the intracellular compartment of 
rat platelets.
17
  In these studies, these workers only found significant amounts of C-CAM 
when 
125
I-labelled rat platelets were solubilised with detergent and immunoprecipitated 
with C-CAM antibodies.  These workers suggested that almost no 
125
I-labelled C-CAM 
could be immunoprecipitated from intact rat platelets under resting or ADP-activated 
conditions.  This study suggested that intracellular expressed C-CAM may play a 
functional role under conditions of platelet activation.  This concept is supported by 
studies of CEACAM1 in leukocytes.  Traditionally, CEACAM1 (formerly known as 
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CD66a) was defined as a neutrophil-specific “activation antigen” in that it is detected in 
low density on resting cells but its surface expression is upregulated upon stimulation 
with the chemotactic peptide FMLP, calcium ionophore A23187 and 12-O-tetradeconoyl-
phorbol-13-acetate.
35 
 Subcellular localization studies revealed that CEACAM1 was 
present in the secondary granules of neutrophils suggesting that antigens could be 
recruited to the cell surface with activation.
36
  In contrast, in mouse spleen T 
lymphocytes, CEACAM1 was not present on the surface of resting cells but was rapidly 
upregulated on CD4
+
 and CD8
+
 T cells after activation with either Con A or anti-CD3 
stimulation.
37
  Overall, these studies in leukocytes are somewhat different from the 
CEACAM1 expression profile that we have observed in murine and human platelets with 
moderate basal expression on the surface of resting platelets with an intracellular pool 
evident (Fig.1A-D).  This was further supported by agonist stimulation using thrombin 
that resulted in upregulation of cell surface expression of CEACAM1 on murine and 
human platelets (Fig.1E-F).     
 
There is now a consensus view that platelet thrombus formation under physiological 
conditions involves platelet adhesion to subendothelial matrix component, Type I 
collagen which becomes exposed by tissue trauma, injury or disease such as 
atherosclerotic plaque formation.  A ‘two-site, two-step’ model for platelet-collagen 
interactions has been proposed that requires the initial engagement of collagen to be 
mediated by the high-affinity receptor integrin α21, followed by activation generated 
through the low-affinity collagen receptor, GPVI.
38,39
 In this model, integrin α21 is now 
thought to have a supportive, rather than a primary role as the adhesive collagen receptor, 
while GPVI is a major platelet-collagen activating receptor that interacts with collagen 
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fibrils via a triplicate GPO sequence (glycine, proline, hydroxyproline) and integrin α21 
interacts with collagen via GFOFER (glycine, phenylalanine, hydroxyproline, glutamic 
acid and arginine).
40-42
  For in vitro studies, we used collagen-related peptide (CRP) as 
the GPVI-selective agonist as this peptide contains ten GPO repeat sequences that serves 
as a potent activator of GPVI-mediated signaling and does not recognize integrin α21.
43
 
In this way, we can differentiate GPVI-mediated platelet responses from integrin α21-
mediated platelet responses.  Signaling through GPVI/FcR gamma chain ITAM- 
dependent pathway is thought to be counterbalanced by proteins bearing ITIM motifs 
such as those contained in members of the Ig-ITIM superfamily.  As mouse platelets lack 
the low-affinity ITAM containing FcRIIa, but contain GPVI/FcR gamma chain ITAM-
dependent pathway, we wanted to test the hypothesis that CEACAM1 may serve as an 
inhibitory co-receptor in platelets to negatively regulate collagen GPVI-mediated platelet 
responses.  Consistent with this hypothesis, Ceacam1
-/-
 platelets displayed hyper-tyrosine 
phosphorylated proteins including PLC gamma 2 following GPVI stimulation compared 
to wild-type platelets indicating modulation of ITAM-associated signaling events in 
murine platelets (Fig. 3). 
 
In order to test this hypothesis, platelet aggregation studies were conducted to examine 
the slope and amplitude of platelet responses of wild-type versus CEACAM1-deficient 
platelets using a range of agonists and dose-dependent ranges including collagen and 
CRP.  In addition, to test specificity of platelet responses, different agonists were selected 
to stimulate different receptor signaling pathways including G-protein-coupled receptors 
using PAR-4 and ADP, calcium ion channels using calcium ionophore and collagen 
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coupled receptors such as acid soluble collagen and CRP.  Ceacam1
-/- 
platelets displayed 
normal platelet aggregation responses over a dose-dependent range of PAR-4, ADP and 
calcium ionophore.  In contrast, Ceacam1
-/-
 platelets displayed enhanced platelet 
aggregation responses over a dose-dependent range of collagen and CRP (Fig.4).  This 
hyper-responsive feature was most evident at subthreshold concentrations of either 
collagen or CRP indicating that CEACAM1 serves to negatively regulate collagen GPVI-
mediated ITAM platelet responses.  Importantly, the fact that the platelet aggregation 
responses to PAR-4, ADP and calcium ionophore were normal reveals that Ceacam1
-/-
 
platelets do not have a global platelet defect and that the defect is restricted to GPVI-
mediated platelet-collagen interactions.    
 
This hyper-responsive feature of Ceacam1
-/-
 platelets with either subthreshold doses of 
collagen or CRP is consistent with the phenotype observed by us and others with 
Pecam1
-/- 
platelets.
1,2 
 The subtle phenotype was most evident at concentrations of 
collagen at 1 μg/mL but was not so evident at higher concentrations of collagen 10-30 
μg/mL.  This was also the case using CRP as the GPVI-selective agonist.  At 0.5 μg/mL 
CRP, wild-type platelets were not responsive while Pecam-1
-/- 
platelets yielded approx. 
70% CRP-mediated platelet aggregation response.  At 5-10 μg/mL CRP, wild-type and 
Pecam-1
-/-
 platelets yielded less hyper-responsive platelet responses.
1,2 
  
 
Platelets from Ceacam1
-/-
 mice exhibited increased adhesion on Type I fibrillar collagen 
but not fibrinogen.  This hyper-responsive adhesion phenotype of Ceacam1
-/- 
platelets on 
Type I fibrillar collagen was evident at all time points.  In addition, Ceacam1
-/-
 platelets 
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displayed a lowered threshold for alpha and dense granule release relative to wild-type 
and Ceacam1
+/-
 platelets following stimulation with GPVI-selective ligand, CRP 
particularly at 0.1-0.5 μg/mL and type I collagen at 1 μg/mL but not G-protein-coupled 
receptor agonist, thrombin.  Overall, these features suggest that in the absence of an 
inhibitory co-receptor, platelets are more responsive to stimulation by collagen agonists 
particularly involving collagen GPVI receptor-mediated signaling.  This trend is 
consistent with CEACAM1 serving as a negative regulator of platelet-collagen 
interactions.   
  
In order to investigate the role of CEACAM1 in thrombus formation in vitro and in vivo, 
we employed intravital microscopy to study thrombus formation in real time and ferric 
chloride-induced vascular injury of mesenteric arterioles and in vitro flow studies on 
immobilised Type I collagen.  Using this ferric chloride-induced vascular injury model 
results in exposure of subendothelial collagens including Type I collagen.  This enables 
collagen GPVI platelet interactions to occur with exposed Type I collagen.  Under these 
conditions, we demonstrated that thrombi formed in mesenteric arterioles following ferric 
chloride injury in CEACAM1 knockout mice were significantly larger in area and 
volume reflecting increased thrombus growth than those formed in wild-type and 
Ceacam1
+/-
 mice (Fig.6B-C).  These differences in thrombus size were consistent over 
time.   In addition, thrombi formed in CEACAM1 knockout mice appear to have greater 
stability than wild-type and Ceacam1
+/-
 mice (Fig.6D).  In addition, this in vivo thrombus 
growth phenotype observed in Ceacam1
-/-
 mice was dependent on the presence of 
collagen GPVI receptor on platelets (Fig. 6E-F).  These data are consistent with 
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CEACAM1 playing a role in negative regulation of thrombus growth in vivo in 
mesenteric arterioles.  In addition, our studies have shown an important role for 
CEACAM1 in regulating thrombus formation on immobilised collagen under in vitro 
flow conditions (Fig.6F).   As CEACAM1 is expressed on platelets, leukocytes and 
endothelium further studies will be required to dissect out the relative importance of 
platelet CEACAM1 versus endothelial CEACAM1 in regulating thrombus growth in 
vivo.  Importantly, CEACAM1 appears to represent a second example of an Ig-ITIM 
superfamily member that plays an important functional role in negatively regulating 
stationary adhesion of platelet-collagen interactions and thrombus growth in vivo, but not 
tethering and rolling of platelets on the thrombogenic collagen surface.   
 
Previous studies with PECAM-1-deficient mice in the ferric chloride induced vascular 
injury model of carotid arteries revealed a subtle defect in the time to 75% vessel 
occlusion.
44  
The mean occlusion rate of Pecam-1
-/-
 mice was shorter than wild-type 
control mice.  However, the magnitude of difference was only very modest.  A more 
noticeable difference was observed in the kinetics of platelet thrombus formation using 
the laser-induced injury model that requires tissue factor generated platelet/fibrin 
thrombus and not Type I collagen exposure.
44
     Therefore, it appears that PECAM-1 and 
CEACAM1 both play a role in negatively regulating platelet-collagen interactions in 
vivo.   
 
In order to examine the consequences of CEACAM1 deficiency in vivo in platelet-
collagen interactions, we utilised a second model of Type I collagen-induced pulmonary 
 25 
thromboembolism.  In this model, type I fibrillar collagen is infused intravenously and 
platelet thrombi are deposited in the lung architecture leading to development of 
pulmonary thromboembolism and restrained breathing that in wild-type mice ultimately 
leads to morbidity.  Using this model, monitoring of the restrained breathing rate of the 
mice revealed that Ceacam1
-/-
 mice have enhanced susceptibility to Type I collagen 
induced pulmonary thromboembolism but not tissue thromboplastin induced pulmonary 
thromboembolism compared to wild-type and Ceacam1
+/-
 mice (Fig.7B and 7D).  
Ceacam1
-/- 
mice showed a reduction in time for restrained breathing following challenge 
with Type I fibrillar collagen compared to wild-type and Ceacam1
+/- 
mice (Fig.7B) 
despite having comparable consumption of platelets (Fig.7A). These data further 
implicate CEACAM1 as a physiological regulator of platelet-collagen interactions in 
vivo.     
 
In conclusion, this study has defined a new inhibitory co-receptor, CEACAM1 present in 
murine and human platelets that is expressed on the surface and in intracellular 
compartments.   CEACAM1 serves as a negative physiological regulator of platelet-
collagen interactions as shown by its hyper-responsive features in collagen and CRP-
mediated platelet aggregation, increased adhesion on Type I collagen and enhanced alpha 
and dense granule release using GPVI-selective ligand.  In vitro and in vivo, CEACAM1 
serves to negatively regulate arteriolar thrombus growth and thrombosis associated with 
Type I collagen induced pulmonary thromboembolism. These negative regulatory 
properties of CEACAM1 may prove to be of physiological benefit in diseased vessels 
such as rupture of atherosclerotic plaques where Type I collagen is exposed.   
 26 
Acknowledgements 
C.Wong, Y.Liu, J. Yip, R. Chand, J. Wee, A. Reheman and L. Oates performed research 
and analysed data; N. Beauchemin supplied the CEACAM1-deficient mice, B. Nieswandt 
supplied the JAQ1 antibody and advice for the GPVI depletion experiment, H. Ni 
directed the in vitro flow experiments and DE Jackson directed the research and wrote the 
paper. 
 
 27 
References 
1.  Jones KL, Hughan SC, Dopheide SM, Farndale RW, Jackson SP and Jackson DE.  
Platelet endothelial cell adhesion molecule-1 is a negative regulator of platelet-collagen 
interactions.  Blood 2001;98(5):1456-1463. 
 
2.  Patil S, Newman DK and Newman PJ.  Platelet endothelial cell adhesion molecule-1 
serves as an inhibitory receptor that modulates platelet responses to collagen.  Blood 
2001;97(6):1727-1732. 
 
3.  Cicmil M, Thomas JM, Leduc M, Bon C and Gibbins JM.  Platelet endothelial cell 
adhesion molecule-1 signaling inhibits the activation of human platelets.  Blood 
2002;99(1):137-144. 
 
4.  Dhanjal TS, Ross EA, Auger JM, McCarty OJ, Hughes CE, Senis JA, Buckley CD 
and Watson SP.  Minimal regulation of platelet activity by PECAM-1.  Platelets 
2007;18(1):56-67.     
 
5.  Pao LI, Badour K, Siminovitch KA and Neel BG.  Nonreceptor protein-tyrosine 
phosphatases in immune cell signaling.  Ann. Rev. Immunol. 2007;25:473-523. 
 
6.  Chemnitz JM, Parry RV, Nichols KE, June CH and Riley JL.  SHP-1 and SHP-2 
associate with immunoreceptor tyrosine-based switch motif of programmed death 1 upon 
 28 
primary human T cell stimulation, but only receptor ligation prevents T cell activation.  J. 
Immunol. 2004;173:945-954. 
 
7.  Okazaki T, Maeda A, Nishimura H, Kurosaki T and Honjo T.  PD-1 immunoreceptor 
inhibits B cell receptor-mediated signaling by recruiting src homology 2-domain 
containing tyrosine phosphatase 2 to phosphotyrosine.  Proc. Natl. Acad. Sci. USA 
2001;98:13866-13871. 
 
8.  Hamerman JA and Lanier LL.  Inhibition of immune responses by ITAM-bearing 
receptors.  Science STKE 2006;320:1-7. 
 
9.  Abram CL and Lovell CA.  The expanding role for ITAM-based signaling pathways 
in immune cells.  Science STKE 2007;377:1-6. 
 
10.  Newland SA, Macaulay IC, Floto AR, de Vet EC, Ouwehand WH, Watkins NA, 
Lyons PA and Campbell DR.  The novel inhibitory receptor G6B is expressed on the 
surface of platelets and attenuates platelet function in vitro.  Blood 2007;109(11):4806-
4809. 
 
11.  Washington AV, Schubert RL, Quigley L, Disipio T, Feltz R, Cho EH and McVivar 
DW.  A TREM family member, TLT-1, is found exclusively in the alpha granules of 
megakaryocytes and platelets.  Blood 2004;104(4):1042-1047. 
 
 29 
12.  Pasquet JM, Quek L, Pasquet S, Poole A, Matthews JR, Lowell C and Watson SP.  
Evidence for a role for SHP-1 in platelet activation by the collagen receptor glycoprotein 
VI.  J. Biol. Chem. 2000;275(37):28526-28531. 
 
13.  Horst AK and Wagener C.  CEA-related CAMs.  Handbook of Experimental 
Pharmacology, Ed Behrens J and Nelson WJ.  Springer-Verlag, Heidelberg, Germany.  
2004;165:284-323. 
 
14.  Beauchemin N, Kunath T, Robitaille J, Chow B, Turbide C, Daniels E and Veillette 
A.  Association of biliary glycoprotein with protein tyrosine phosphatase SHP-1 in 
malignant colon epithelial cells.  Oncogene 1997;14:783-790. 
 
15.  Huber M, Izzi L, Grondin P, Houde C, Kunath T, Veillette A and Beauchemin N.  
The carboxy-terminal region of biliary glycoprotein controls its tyrosine phosphorylation 
and association with protein-tyrosine phosphatases SHP-1 and SHP-2 in epithelial cells.  
J. Biol. Chem. 1999;274(1):335-344. 
 
16.  Nagaishi T, Pao L, Lin SH, Iijima H, Kaser A, Qiao SW, Chen Z, Glickman J, Najjar 
SM, Nakajima A, Neel BG and Blumberg RS.  SHP1 phosphatase-dependent T cell 
inhibition by CEACAM1 adhesion molecule isoforms.  Immunity 2006;25(5):769-781. 
 
 30 
17.  Hansson M, Odin P, Johansson S and Obrink B.  Comparison and functional 
characterization of C-CAM, glycoprotein IIb/IIIa and integrin beta 1 in rat platelets.  
Thromb. Res. 1990;58(1):61-73. 
 
18.  Leung N, Turbide C, Olson M, Marcus V, Jothy S and Beauchemin N.  Deletion of 
the carcinoembryonic antigen-related cell adhesion molecule 1 (Ceacam1) gene 
contributes to colon tumor progression in a murine model of carcinogenesis.  Oncogene 
2006;25:5527-5536. 
 
19.  Nieswandt B, Bergmeier W, Schulte V, Rackebrandt K, Gessner JE and Zirngibi H.  
Expression and function of the mouse collagen receptor glycoprotein VI is strictly 
dependent on its association with the FcR gamma chain.  J. Biol. Chem. 
2000;275(31):23998-24002. 
 
20.  Bergmeier W, Rackebrandt K, Schroder W, Zirngibl H and Nieswandt B.  Structural 
and functional characterization of the mouse von Willebrand factor receptor GPIb-IX 
with novel monoclonal antibodies.  Blood 2000;95:886-893. 
 
21.  Mendrick DL, Kelly DM, duMont SS and Sandstrom DJ.  Glomerular epithelial and 
mesangial cells differentially modulate the binding specificities of VLA-1 and VLA-2.  
Lab Invest. 1995;72:367-375. 
 
 31 
22.  Maecker HT, Todd SC and Levy S.  The tetraspanin superfamily: molecular 
facilitators.  FASEB J. 1997;11(6):428-442. 
 
23.  Massberg S, Gawaz M, Gruner S, Schulte V, Konrak I, Zohlnhofer D, Heinzmann U 
and Neiswandt B.  A crucial role of glycoprotein VI for platelet recruitment to the injured 
arterial wall in vivo.  J. Exp. Med. 2003;197(1):41-49. 
   
24.  Yasuda M, Hasunuma Y, Adachi H, Sekine C, Sakanishi T, Hashimoto H, Ra C, 
Yagita H and Okumura K.  Expression and function of fibronectin binding integrins on 
rat mast cells.  Int. Immunol. 1995;7:251-258. 
 
25.  Trowbridge IS, Lesley H, Schulte R, Hyman R and Trotter J.  Biochemical 
characterization and cellular distribution of a polymorphic murine cell-surface 
glycoprotein expressed on lymphoid tissues.  Immunogenetics 1982;15:299-312. 
 
26.  Yan HC, Pilewski JM, Zhang Q, DeLisser HM, Romer L and Albelda SM.  
Localization of multiple functional domains on human PECAM-1 (CD31) by monoclonal 
antibody epitope mapping.  Cell Adhes Commun. 1995;3(1):45-66. 
 
27. Wee JL and Jackson DE.  The Ig-ITIM superfamily member of PECAM-1 regulates 
the “outside-in” signaling properties of integrin alphaIIbbeta3 in platelets.  Blood 
2005;106(12):3816-3823. 
 
 32 
28.  Yuan Y, Kulkarni S, Ulsemer P, Cramer SL, Yap CL, Nesbitt WS, Harper I, Mistry 
N, Dopheide SM, Hughan SC, Williamson D, de la Salle C, Salem HH, Lanza F and 
Jackson SP.  The von Willebrand factor-glycoprotein Ib/IX/V interaction induces actin 
polymerization and cytoskeletal reorganization in rolling platelets and glycoprotein 
Ib/V/IX-transfected cells.  J. Biol. Chem. 1999;274(51):36241-36251. 
 
29.  Jackson DE, Ward CM, Wang R and Newman PJ.  The Protein-tyrosine phosphatase 
SHP-2 binds platelet/endothelial cell adhesion molecule-1 (PECAM-1) and forms a 
distinct signaling complex during platelet aggregation.  J. Biol. Chem. 
1997;272(11):6986-6993. 
 
30.  Goschnick MW, Lau LM, Wee JL, Liu YS, Hogarth PM, Robb LM, Hickey MJ, 
Wright MD and Jackson DE.  Impaired ‘outside-in’ integrin alphaIIbbeta3 signaling and 
thrombus stability in TSSC6-deficient mice.  Blood 2006;108(6):1911-1918.  
 
31.  Ni H, Denis CV, Subbarao S, Degen JL, Sato TN, Hynes RO and Wagner DD.  
Persistence of platelet thrombus formation in arterioles of mice lacking both von 
Willebrand factor and fibrinogen.  J. Clin. Invest. 2000;106(3):385-392. 
 
32.  He L, Pappan DG, Grenache DG, Li Z, Tollefsen DM, Santoro SA and Zutter MM.  
The contribution of the α21 integrin to vascular thrombosis in vivo.  Blood 
2003;102:3652-3657. 
 
 33 
33.   Tsui HW, Siminovitch KA, de Souza L and Tsui FW.  Motheaten and viable 
motheaten mice have mutations in the haematopoietic cell phosphatase gene.  Nat. Genet. 
1993;4(2):124-129. 
 
34.  Pasquet JM, Quek L, Pasquet S, Poole A, Matthews JR, Lowell C and Watson SP.  
Evidence for a role for SHP-1 in platelet activation by the collagen receptor glycoprotein 
VI.  J. Biol. Chem. 2000;275(37):28256-28531. 
 
35.  Skubitz KM, Ducker TP and Goueli SA.  CD66 monoclonal antibodies recognise a 
phosphotyrosine-containing protein bearing a carcinoembryonic antigen cross-reacting 
antigen on the surface of human neutrophils.  Journal of Immunology 1992;148(3):852-
860. 
 
36.  Ducker TP and Skubitz KM.  Subcellular localization of CD66, CD67, and NCA in 
human neutrophils.  Journal of Leukocyte Biology 1992;52(1):11-16. 
 
37.  Nakajima A, Iijima H, Neurath MF, Nagaishi T, Nieuwenhuis EE, Raychowdhury R, 
Glickman J, Blau DM, Russell S, Holmes KV, and Blumberg RS.  Activation-induced 
expression of carcinoembryonic antigen-cell adhesion molecule 1 regulates mouse T 
lymphocyte function.  Journal of Immunology 2002;168:1028-1035. 
 
 34 
38.  Santoro SA, Walsh JJ, Staatz WD and Baranski KJ.  Distinct determinants on 
collagen support alpha2 beta1 integrin-mediated platelet adhesion and platelet activation.  
Cell Regulation 1991;2(11):905-913. 
 
39.  Morton LF, Hargreaves PG, Farndale RW, Young RD and Barnes MJ.  Integrin 
alpha 2 beta 1-independent activation of platelets by simple collagen-like peptides: 
collagen tertiary (triple-helical) and quarternary (polymeric) structures are sufficient 
alone for alpha 2 beta 1-independent platelet reactivity.  Biochem J. 1995;306(2):337-
344. 
 
40.  Nieswandt B and Watson SP.  Platelet-collagen interaction: is GPVI the central 
receptor? Blood 2003;102(2):449-461. 
 
41.  Nieswandt B, Brakebusch C, Bergmeier W, Schulte V, Bouvard D, Mokhtari-Nejad 
R, Lindhout T, Hemmsverk JW, Zirngibil H and Fassier R.  Glycoprotein VI but not 
alpha2beta1 integrin is essential for platelet interaction with collagen.  EMBO Journal 
2001;20(9):2120-2130. 
 
42.  Chen H, Locke D, Liu Y, Liu C and Kahn ML.  The platelet receptor GPVI mediates 
both adhesion and signaling responses to collagen in a receptor density-dependent 
fashion.  Journal of Biological Chemistry 2002;277(4):3011-3019. 
 
 35 
43.  Kato K, Kanaji T, Russell S, Kunicki TJ, Furihata K, Kanaji S, Marchese P, 
Reininger A, Ruggeri ZM and Ware J.  The contribution of glycoprotein VI to stable 
platelet adhesion and thrombus formation illustrated by targeted gene deletion.  Blood 
2003;102(5):1701-1707. 
 
44.  Falati S, Patil S, Gross PL, Stapleton M, Merrill-Skoloff G, Barrett NE, Pixton KL, 
Weiler H, Cooley B, Newman DK, Newman PJ, Furie BC, Furie B and Gibbins JM.  
Platelet PECAM-1 inhibits thrombus formation in vivo.  Blood 2006;107:535-541. 
 
 
 
 
 36 
Figure Legends 
Figure 1.  CEACAM1 is expressed on the surface and in intracellular pools in 
murine and human platelets. 
A.  Flow cytometric analysis of CEACAM1 surface and total expression on resting 
murine platelets.  Platelets were stained with a polyclonal anti-murine CEACAM1 2457 
antibody followed by a secondary FITC-conjugated anti-rabbit antibody.  Normal rabbit 
serum and Ceacam1
-/-
 platelets were included as negative controls.  Data was collected 
through a live platelet gate based on forward versus side scatter profiles on a FACS 
Canto flow cytometer.  Results are cumulative data derived from three independent 
experiments and represented as mean fluorescence intensity (MFI) ± SEM.     
B.  Flow cytometric analysis of CEACAM1 surface and total expression on resting 
human platelets.  Platelets were stained with a monoclonal anti-human CEACAM1 
4D1C2 antibody followed by a secondary FITC-conjugated anti-mouse antibody.  
Normal mouse IgG and Ceacam1
-/-
 platelets were included as negative controls.  Data 
was collected through a live platelet gate based on forward versus side scatter profiles on 
a FACS Canto flow cytometer.  Results are cumulative data derived from three 
independent experiments and represented as mean fluorescence intensity (MFI) ± SEM.     
C-D.  Representative histogram profiles of CEACAM1 surface and total expression on 
resting murine and human platelets.  CEACAM1 surface and total expression was 
determined as described in A and B. 
E.  Agonist stimulation of murine platelets using thrombin (0.25-1.00 U/mL) over a dose-
dependent range.  CEACAM1 surface expression was determined as described in A.   
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F.  Agonist stimulation of human platelets using thrombin (0.25-1.00 U/mL) over a dose-
dependent range.  CEACAM1 surface expression was determined as described in B. 
G.  Flow cytometric analysis of CEACAM1 surface expression on resting murine 
platelets from wild-type versus Ceacam1
+/-
 and Ceacam1
-/-
 mice.  CEACAM1 surface 
expression was determined as described in A. 
H. Representative histogram profiles of CEACAM1 surface expression on resting murine 
platelets from wild-type versus Ceacam1
+/-
 and Ceacam1
-/-
 mice.     
 
Figure 2.  Ceacam1
-/-
 platelets demonstrate increased adhesion on immobilised Type 
I fibrillar collagen. 
A.  Wild-type, Ceacam1
+/-
 and Ceacam1
-/-
 platelets were allowed to adhere to type I 
fibrillar collagen (50 μg/mL) in the absence of magnesium, or to plates coated with 
bovine serum albumin (50 μg/mL) for 15, 30, 45 or 60 minutes at 37oC.  After removal of 
non-adherent platelets, adherent platelets were measured as described in Materials and 
Methods.  Each assay was performed in triplicate and is representative of three 
independent experiments.  Each data point represents platelet adhesion per high powered 
field and was expressed as the mean ± SEM.  Note that wild-type, Ceacam1
+/-
 and 
Ceacam1
-/-
 platelets bound to a similar extent on BSA-coated platelets, where at all time 
points, Ceacam1
-/- 
platelets showed higher levels of adhesion to type I fibrillar collagen 
compared to wild-type and Ceacam1
+/- 
platelets (***P<0.005, n=3).  B.  As described in 
A, but for platelet adhesion on fibrinogen (50 μg/mL) for wild-type, Ceacam1+/- and 
Ceacam1
-/-
 platelets for 15, 30, 45 or 60 minutes at 37
o
C.      
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C.  Representative micrographs of platelet adhesion on Type I fibrillar collagen (50 
μg/mL) for wild-type and Ceacam1-/- platelets over time.  Adherent platelets were fixed 
and imaged for DIC microscopy (x 63 oil objective).  
 
Figure 3.  Ceacam1
-/-
 platelets display hyper-phosphorylated proteins including 
PLC-gamma2 following CRP stimulation over time. 
A.  Tyrosine phosphorylation in whole-cell platelet lysates from wild-type and Ceacam1
-
/- 
mice were stimulated with CRP (10 μg/mL) over a 3 min time frame.  30 μg of each 
platelet lysate was loaded onto a 10% SDS-PAGE gel and tyrosine phosphorylation 
detected on the western blot using a HRP-conjugated anti-phosphotyrosine RC20 
antibody.  Erk-2 blot (lower panel) was included as a protein loading control.  This is a 
representative blot of three experiments performed.  B.  PLC2 was immunoprecipitated 
from lysates of wild-type or Ceacam1
-/-
 platelets stimulated by CRP (10 μg/mL) at T=0 
and T=90 seconds and immunoblotted for phosphotyrosine using a HRP-conjugated anti-
phosphotyrosine RC20 antibody.  PLC2 antigen is included as a loading control of the 
immunoprecipitates (lower panel).  Relative intensity of tyrosine phosphorylated PLC2 
to total PLC2 antigen was quantitated using Image J software version 1.40g from three 
replicate experiments. 
 
Figure 4.  Ceacam1
-/-
 platelets show hyper-responsive aggregation in response to 
stimulation with GPVI-selective agonists. 
Aggregation responses of PRP (platelet count adjusted to 100 x10
9
/l) for wild-type and 
Ceacam1
-/-
 mice were determined following activation with different concentrations of 
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various agonists: PAR-4 agonist peptide (100-250 μM), ADP (5-20 μM), calcium 
ionophore (0.3-2.5 μg/mL), collagen-related peptide (0.62-2.5 μg/mL) and collagen (1.5-
4 μg/mL) respectively.  Note that Ceacam1-/- platelets are hyper-responsive in collagen 
and CRP-induced platelet aggregation.  These experiments are representative of at least 
three independent experiments performed.   
    
Figure 5.  Ceacam1
-/-
 platelets display a lower threshold in alpha and dense granule 
release in response to stimulation with GPVI-selective agonists. 
A.  Wild-type (black bars), Ceacam1
+/- 
(gray bars) and Ceacam1
-/-
 platelets (white bars) 
were stimulated with varying concentrations of GPVI-selective agonists including type I 
fibrillar collagen in the absence of magnesium and CRP, or with thrombin.  The amount 
of 5-hydroxytryptamine released was measured as described in Materials and Methods.  
The assays were performed in triplicate, and the results expressed as the mean ± SEM.  
These results are representative of three independent experiments.  Note that the release 
of dense granular contents in response to stimulation at subthreshold levels of GPVI-
selective agonists was elevated in Ceacam1
-/- 
platelets compared to the wild-type and 
Ceacam1
+/-
 platelets. 
B.  Surface expression of P-selectin (alpha granule release) was determined for washed 
platelets stimulated by thrombin, PAR-4 agonist peptide or collagen-related peptide 
(CRP) at different concentrations and then stained with either a buffer control and FITC-
P-selectin mAb for both wild-type and Ceacam1
-/- 
platelets.  FITC-labelled samples were 
analyzed on a FACS Canto analyzer.  Results are representative of three independent 
experiments. 
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Figure 6.  Thrombi are larger and more stable in Ceacam1
-/-
 mice both in vitro and 
in vivo. 
A.  Images of thrombus formation in response to ferric chloride induced vascular injury 
was visualized in arterioles of wild-type versus Ceacam1
-/-
 mice over time.  The different 
lengths of time after ferric chloride application are indicated.  Note that Ceacam1
-/-
 
arterioles formed larger thrombi over time compared to wild-type control arterioles 
(n=15).     
B-D.  Quantitative analysis of arterial thrombogenesis of wild-type, Ceacam1
+/-
 and 
Ceacam1
-/- 
arterioles.  Compared to wild-type arterioles, Ceacam1
-/-
 arterioles exhibited a 
significant increase in thrombus area over two minutes (6212±268.7 versus 3294±223.4 
and 2859±294 μm2; ***P<0.0001, n=15), showed greater stability in thrombi formed 
(4.07±0.37 versus 2.40±0.21 and 1.05±0.12; ***P<0.001, n=15) and increased thrombus 
volume (122400±6794 versus 49430±4602 and 63680±5478 μm3; ***P<0.0001, n=15).  
The primary stability of the thrombi was scored from 1 to 10, with 1 being 0-10% 
occupancy and 10 being 91-100% occupancy (ie. complete vessel occlusion) monitored 
over time. 
E-F.  Platelet thrombus formation following inhibition of GPVI using monoclonal 
antibody JAQ1 administration to Ceacam1
+/+
 and Ceacam1
-/-
 mice compared to control 
IgG treated Ceacam1
+/+
 and Ceacam1
-/-
 or untreated Ceacam1
+/+ 
and Ceacam1
-/-
 mice.  
Mice received either 100 μg Control IgG or JAQ1 antibody and were left for 5 days 
before ferric chloride injury and intravital microscopy.  Compared to untreated Ceacam1
-
/- 
or control IgG treated Ceacam1
-/-
 arterioles, JAQ1 treated Ceacam1
-/-
 arterioles 
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exhibited a 3-fold reduction in thrombus volume over two minutes (135500±2137 versus 
134000±1837 compared to 40400±1127 μm3; ***P<0.001, n=10 arterioles from 3 
mice/group) and a 2-fold reduction in stability score over two minutes (6.150±0.2115 
versus 5.700±0.3000 compared to 3.350±0.2115; ***P<0.001, n=10 arterioles from 3 
mice/group).  In contrast, compared to untreated Ceacam1
+/+ 
or control IgG treated 
Ceacam1
+/+
 arterioles, JAQ1 treated Ceacam1
+/+
 arterioles exhibited a 3-fold reduction 
in thrombus volume over two minutes (107800±3526 versus 102100±2607 compared to 
32050±599 μm3; ***P<0.001, n=10 arterioles from 3 mice/group) and a modest 
reduction in stability score over two minutes (2.750±0.2609 versus 3.000±0.2357 
compared to 2.150±0.0764; ***P<0.001, n=10 arterioles from 3 mice/group). 
 
G.  DiOC6-labelled whole blood of wild-type, Ceacam1
+/-
 and Ceacam1
-/-
 mice was 
perfused over 100 μg/mL Type I fibrillar collagen-coated microslides at a wall shear rate 
of 1800 seconds
-1.
. Thrombi were imaged at 4 minutes of blood flow by confocal 
microscopy (x60, 1-μm sections) and thrombus was quantified using Slidebook software 
(Intelligent Imaging Innovations Inc., Denver, CO, USA).  Each data point showed on the 
graph represents the thrombus volume for each individual mouse performed 
independently. 
 
Figure 7.  Ceacam1
-/-
 mice are more susceptible to Type I collagen-induced 
pulmonary thromboembolism. 
A.  The percentage reduction in platelet count over three minutes for wild-type, 
Ceacam1
+/- 
and Ceacam1
-/-
 mice after intravenous injection of 350 μg/kg type I fibrillar 
 42 
collagen was determined.  Note that wild-type, Ceacam1
+/- 
and Ceacam1
-/- 
mice showed a 
similar reduction in platelet count over time (77.24±2.246 versus 73.49±3.157 and 
74.21±3.507%; P>0.05, n=20). 
B.  The time until restrained breathing, quantified by a breathing interval of 10 secs, for 
wild-type and Ceacam1
-/- 
mice following intravenous injection of 350 μg/kg of type I 
fibrillar collagen.  Note that Ceacam1
-/-
 mice showed enhanced susceptibility to type I 
collagen-induced pulmonary thromboembolism compared to wild-type control mice 
(343.5±23.73 versus 327.0±28.29 and 252.1±15.39 secs; **P<0.001, n=20). 
C.  The percentage reduction in platelet count over three minutes for wild-type and 
Ceacam1
-/-
 mice after intravenous injection of 0.200 μl/g tissue thromboplastin 
Thromborel S was determined.  Note that wild-type and Ceacam1
-/- 
mice showed a 
similar reduction in platelet count over time (94.30±2.162 versus 93.22±1.755%; P>0.05, 
n=10). 
D.  The time until restrained breathing, quantified by a breathing interval of 10 secs, for 
wild-type and Ceacam1
-/- 
mice following intravenous injection of 0.200 μl/g tissue 
thromboplastin Thromborel S was determined.  Note that Ceacam1
-/-
 mice showed equal 
susceptibility to tissue thromboplastin induced pulmonary thromboembolism compared to 
wild-type control mice (214.2±4.052 versus 223.8±7.979 secs; P>0.05, n=10). 
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